The Coronavirus Disease-2019 (COVID-19) pandemic has brought all healthcare facilities across the world to their limits. A plethora of therapeutic options have been tried; whilst some are evidence-based, some are not. A few novel drugs have been launched, although most of the drugs, including combination therapies, used in COVID-19 management are repurposed ones. Some drugs have received emergency use authorizations and are lacking robust safety data. Hence, it is pertinent to evaluate the safety profile of all these drugs on a large scale.
In search of an effective definitive and/or supportive treatment of COVID-19, various studies have been conducted or presently underway within a very short time. Convincing short- and long-term safety data of many investigational drugs (and their combinations) are lacking. Given the unmet need for evaluation of the safety profile of these drugs, both new and re-purposed ones, in various populations in the management of COVID-19, it is necessary to take a pragmatic approach. Randomized database studies, chart review, claims data, voluntary reporting, administrative data analyses, computer monitoring, direct care observations, and patient monitoring could be some of the feasible research options in this regard.
This particular issue is looking for contributions focusing on diverse aspects of medication (both approved and unapproved ones) safety in patients with COVID-19. Research on COVID-19 vaccines is out of scope. Original Articles, Brief Communications, Reviews (narrative or systematic, including meta-analysis), Case Reports, and Letters will be considered. Opinions/Commentaries on existing policies and healthcare practices in COVID-19 are also welcome. Evaluation of both physician- and patient-reported outcomes (short- and long-term) will be encouraged.
The Coronavirus Disease-2019 (COVID-19) pandemic has brought all healthcare facilities across the world to their limits. A plethora of therapeutic options have been tried; whilst some are evidence-based, some are not. A few novel drugs have been launched, although most of the drugs, including combination therapies, used in COVID-19 management are repurposed ones. Some drugs have received emergency use authorizations and are lacking robust safety data. Hence, it is pertinent to evaluate the safety profile of all these drugs on a large scale.
In search of an effective definitive and/or supportive treatment of COVID-19, various studies have been conducted or presently underway within a very short time. Convincing short- and long-term safety data of many investigational drugs (and their combinations) are lacking. Given the unmet need for evaluation of the safety profile of these drugs, both new and re-purposed ones, in various populations in the management of COVID-19, it is necessary to take a pragmatic approach. Randomized database studies, chart review, claims data, voluntary reporting, administrative data analyses, computer monitoring, direct care observations, and patient monitoring could be some of the feasible research options in this regard.
This particular issue is looking for contributions focusing on diverse aspects of medication (both approved and unapproved ones) safety in patients with COVID-19. Research on COVID-19 vaccines is out of scope. Original Articles, Brief Communications, Reviews (narrative or systematic, including meta-analysis), Case Reports, and Letters will be considered. Opinions/Commentaries on existing policies and healthcare practices in COVID-19 are also welcome. Evaluation of both physician- and patient-reported outcomes (short- and long-term) will be encouraged.
